Clinical Trial Update: Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on 2 weeks of dapagliflozin in subjects with impaired glucose homeostasis examining nocturnal substrate oxidation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prediabetic State

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Maastricht University | Conditions: Prediabetic State, Substrate Oxidation | Phase 4 | Status: COMPLETED